155 related articles for article (PubMed ID: 38630860)
21. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
[TBL] [Abstract][Full Text] [Related]
22. Dry powder inhalation, part 2: the present and future.
de Boer AH; Hagedoorn P; Grasmeijer F
Expert Opin Drug Deliv; 2022 Sep; 19(9):1045-1059. PubMed ID: 35984322
[TBL] [Abstract][Full Text] [Related]
23. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
24. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
26. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries.
Lewis A; Torvinen S; Dekhuijzen PN; Chrystyn H; Watson AT; Blackney M; Plich A
BMC Health Serv Res; 2016 Jul; 16():251. PubMed ID: 27406133
[TBL] [Abstract][Full Text] [Related]
27. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
Virchow JC; Weuthen T; Harmer QJ; Jones S
Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
[TBL] [Abstract][Full Text] [Related]
28. Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion.
Baloira A; Abad A; Fuster A; García Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL; González-Torralba F
Int J Chron Obstruct Pulmon Dis; 2021; 16():1021-1033. PubMed ID: 33907390
[TBL] [Abstract][Full Text] [Related]
29. Optimizing drug delivery in COPD: The role of inhaler devices.
Rogliani P; Calzetta L; Coppola A; Cavalli F; Ora J; Puxeddu E; Matera MG; Cazzola M
Respir Med; 2017 Mar; 124():6-14. PubMed ID: 28284323
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
31. Carrier free indomethacin microparticles for dry powder inhalation.
Ceschan NE; Bucalá V; Mateos MV; Smyth HDC; Ramírez-Rigo MV
Int J Pharm; 2018 Oct; 549(1-2):169-178. PubMed ID: 30071308
[TBL] [Abstract][Full Text] [Related]
32. Device errors in asthma and COPD: systematic literature review and meta-analysis.
Chrystyn H; van der Palen J; Sharma R; Barnes N; Delafont B; Mahajan A; Thomas M
NPJ Prim Care Respir Med; 2017 Apr; 27(1):22. PubMed ID: 28373682
[TBL] [Abstract][Full Text] [Related]
33. Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care.
Capstick TGD; Gudimetla S; Harris DS; Malone R; Usmani OS
Clin Drug Investig; 2024 Feb; 44(2):109-114. PubMed ID: 38198116
[TBL] [Abstract][Full Text] [Related]
34. Evaluating dry powder inhalers: From in vitro studies to mobile health technologies.
Ari A; Alhamad BR
Respir Med; 2023; 215():107281. PubMed ID: 37244487
[TBL] [Abstract][Full Text] [Related]
35. Dry powder inhalers for optimal drug delivery.
Newman SP
Expert Opin Biol Ther; 2004 Jan; 4(1):23-33. PubMed ID: 14680466
[TBL] [Abstract][Full Text] [Related]
36. Smart dry powder inhalers and intelligent adherence management.
Häußermann S; Arendsen LJ; Pritchard JN
Adv Drug Deliv Rev; 2022 Dec; 191():114580. PubMed ID: 36273513
[TBL] [Abstract][Full Text] [Related]
37. The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices.
Roche N; Dekhuijzen PN
J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):311-27. PubMed ID: 26824873
[TBL] [Abstract][Full Text] [Related]
38. High inhaler resistance does not limit successful inspiratory maneuver among patients with asthma or COPD.
Vartiainen VA; Lavorini F; Murphy AC; Rabe KF
Expert Opin Drug Deliv; 2023 Mar; 20(3):385-393. PubMed ID: 36820500
[TBL] [Abstract][Full Text] [Related]
39. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
Lin YW; Wong J; Qu L; Chan HK; Zhou QT
Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
[TBL] [Abstract][Full Text] [Related]
40. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
